COMMUNIQUÉ DE PRESSE publié le 28/11/2023 à 12:40, il y a 2 années 5 mois The Phase 1a/1b Human Clinical Trial of NV-CoV-2, the Company’s Broad-Spectrum Antiviral Drug, Has Successfully Completed the First Part (Phase 1a), Reports NanoViricides
COMMUNIQUÉ DE PRESSE publié le 15/11/2023 à 12:45, il y a 2 années 6 mois NanoViricides Has Filed its Quarterly Report - NV-387 Broad-Spectrum Antiviral in Clinical Trials Has Additional Applications
COMMUNIQUÉ DE PRESSE publié le 14/11/2023 à 12:45, il y a 2 années 6 mois Broad-Spectrum Antiviral NV-387 (NV-CoV-2) in Phase 1a/1b Clinical Trial is Highly Effective in an Animal Model for MPox and Smallpox Drug Development
COMMUNIQUÉ DE PRESSE publié le 16/10/2023 à 12:45, il y a 2 années 7 mois NanoViricides, Inc. Has Filed its Annual Report: Broad-spectrum Antiviral NV-387 (NV-CoV-2) in Phase 1a/1b Clinical Trial is Highly Active Against Coronaviruses as well as RSV
COMMUNIQUÉ DE PRESSE publié le 12/10/2023 à 12:45, il y a 2 années 7 mois NanoViricides, Inc. to Present at the Partnership Opportunities in Drug Delivery Conference in Boston on October 16, 2023 at 6:07pm ET
COMMUNIQUÉ DE PRESSE publié le 21/08/2023 à 12:45, il y a 2 années 9 mois The Phase 1a/1b Human Clinical Trial of NV-CoV-2, the Company’s Broad-Spectrum Antiviral Drug, is Progressing Successfully, Reports NanoViricides
COMMUNIQUÉ DE PRESSE publié le 11/07/2023 à 12:45, il y a 2 années 10 mois Company’s Broad-Spectrum Antiviral NV-387 Has Demonstrated Excellent Effectiveness in RSV in a Lethal Lung Disease Animal Model, Reports NanoViricides
COMMUNIQUÉ DE PRESSE publié le 06/07/2023 à 12:45, il y a 2 années 10 mois Clinical Trial of Broad-Spectrum Antiviral Drug NV-CoV-2 is Progressing Well, Says NanoViricides - NV-CoV-2 is Positioned to Fulfill Many Unmet Medical Needs
COMMUNIQUÉ DE PRESSE publié le 29/06/2023 à 12:45, il y a 2 années 10 mois NanoViricides Announces that Clinical Trials of Its Broad-Spectrum Antiviral Drug NV-CoV-2 Have Begun
COMMUNIQUÉ DE PRESSE publié le 31/05/2023 à 12:40, il y a 2 années 11 mois NanoViricides, Inc. to Present at the BIO International Convention in Boston on June 5th, 2023 at 3:15pm ET
Publié le 26/05/2026 à 15:00, il y a 2 heures 38 minutes Besluiten Gewone en Buitengewone Algemene Vergaderingen
Publié le 26/05/2026 à 15:00, il y a 2 heures 38 minutes Resolutions Ordinary and Extraordinary General Meetings
Publié le 26/05/2026 à 07:59, il y a 9 heures 39 minutes Saint-Gobain signe un accord de cession de son activité de distribution de carrelage dans les pays nordiques
Publié le 26/05/2026 à 07:59, il y a 9 heures 39 minutes Saint-Gobain has signed an agreement for the sale of its Tiles Distribution business in the Nordics
Publié le 25/05/2026 à 18:00, il y a 23 heures 38 minutes Déclaration des transactions sur actions propres réalisées du 18/05/2026 au 24/05/2026
Publié le 26/05/2026 à 14:30, il y a 3 heures 8 minutes Klondike Gold Announces 2026 Diamond Drilling Program Underway to Update and Expand Gold Mineral Resources
Publié le 26/05/2026 à 14:30, il y a 3 heures 8 minutes Predictiv AI Announces Strategic Healthcare Partnership and CloudRep AI Integration with Clinicmaster Following Successful Multi-Clinic Pilot Deployments
Publié le 26/05/2026 à 14:30, il y a 3 heures 8 minutes In the Ebola Emergency, NV-387 is Ready to be Shipped to DRC, and It Compares Favorably as a Treatment for Ebola Versus Possible Options, Says NanoViricides
Publié le 26/05/2026 à 14:15, il y a 3 heures 23 minutes Worksport (NASDAQ:WKSP) Secures U.S. Patent For 'Industry-First' Zerofrost Heat Pump Through Its Subsidiary, Terravis Energy
Publié le 26/05/2026 à 14:00, il y a 3 heures 38 minutes Ameriwest Critical Metals Provides Q2 2026 Corporate Update and Announces Live CEO Investor Webinar
Publié le 26/05/2026 à 16:30, il y a 1 heure 7 minutes M1 Kliniken AG: Capital reduction through cancellation of treasury shares successfully completed
Publié le 26/05/2026 à 16:15, il y a 1 heure 23 minutes R. STAHL AG Management Board member Dr. Claus Bischoff resigns from his office as Management Board member at his own request and for personal reasons and will leave by mutual agreement as of 31 May 20
Publié le 26/05/2026 à 16:03, il y a 1 heure 35 minutes EQS-Adhoc: R. Stahl AG: Dr. Claus Bischoff resigns from his office as member of the Management Board of R. STAHL Aktiengesellschaft with immediate effect and will leave the company as of 31 May 2026.
Publié le 26/05/2026 à 16:01, il y a 1 heure 37 minutes EQS-Adhoc: Tempton Personaldienstleistungen GmbH announces full redemption of bonds and the exercise of the early redemption option
Publié le 26/05/2026 à 15:37, il y a 2 heures 1 minute FGC plans regional rail transport in Catalonia with IVU.rail
